Details of the Drug Combinations

General Information of This Drug (ID: DM25YLM)

Drug Name

GSK2981278 DM25YLM

Synonyms

ROR gama modulator 1; 1474110-21-8; UNII-L49V5G013I; L49V5G013I; N-(4-ethylphenyl)-3-(hydroxymethyl)-N-isobutyl-4-((tetrahydro-2H-pyran-4-yl)methoxy)benzenesulfonamide; GTPL9661; SCHEMBL15352875; LZLBRISQTJVZNP-UHFFFAOYSA-N; MolPort-044-561-790; EX-A1179; ZINC142250256; AKOS030526564; CS-5449; GSK-2981278; HY-19770; N-(4-ethylphenyl)-3-(hydroxymethyl)-N-(2-methylpropyl)-4-(oxan-4-ylmethoxy)benzenesulfonamide; Benzenesulfonamide, N-(4-ethylphenyl)-3-(hydroxymethyl)-N-(2-methylpropyl)-4-((tetrahydro-2H-pyran-4-yl)

Indication

Disease Entry	ICD 11	Status	REF
Plaque psoriasis	EA90.0	Phase 2	[1]
------------------------------------------------------------------------------------

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

1 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
GSK2981278 + Idarubicin	DCYMBV1	Idarubicin	Glioblastoma? (Cell Line: T98G)	[2]
------------------------------------------------------------------------------------

References

1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.